

FIFTH YEAR ANNIVERSARY

CELEBRATING THE
Art & Science
of Ketamine Therapy:

A FOCUS ON STANDARDS
OF CARE & ETHICS

JUNE 9-11, 2022 | AUSTIN, TX

Who Is ASKP³

The American Society of Ketamine Physicians, Psychotherapists, and Practitioners is a non-profit group of professionals dedicated to the safe clinical use of ketamine for mental health disorders and pain conditions.

ASKP³ Mission Statement

Our mission is to further awareness and education regarding safe, effective and ethical therapeutic use of ketamine

Who Is ASKP³

Our vision is to advance the treatment of mental and physical health through the use of ketamine by:

- Establishing scientific, ethical and transparent standards among practitioners
- Advancing the quality of care through the furthering of knowledge, the exchange of ideas, and research
- Fostering multidisciplinary collaboration to improve patient outcomes
- Educating the clinical communities about all aspects of this treatment modality
- Building awareness and understanding among the general population, legislators, regulators and payers
- Welcoming relationships that support the development of other psychedelic therapies

Continuing Education

MD

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the American Society of Ketamine Physicians. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the live and enduring formats for this educational activity for a maximum of 18.50 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. **Live activity date(s): June 9, 2022 - June 11, 2022**

CRNA

This program has been prior approved by the American Association of Nurse Anesthesiology for 15.50 Class A CE credits; Code Number 1042186; Expiration Date 6/11/2022. AANA designates this program as meeting the criteria for up to 1.50 CE Credits in pharmacology/therapeutics.



Schedule At-A-Glance

THURSDAY, JUNE 9

12:00 PM - 7:00 PM	Registration	Congressional Foyer
1:00 PM - 5:15 PM	Introductory Pre-Lectures (Additional Ticket Purchase Required)	Sage
6:00 PM - 7:30 PM	Welcome Cocktail Reception Sponsored by Ketamine Media	Congressional Foyer

FRIDAY, JUNE 10

7:00 AM - 5:30 PM	Registration	Congressional Foyer
7:00 AM - 8:00 AM	Breakfast Sponsored by Beyond Marketing	Congressional A
8:15 AM - 11:30 AM	Main Stage Presentations	Congressional B
11:30 AM - 12:30 PM	Lunch	Congressional A
12:30 PM - 3:10 PM	Main Stage Presentations	Congressional B
3:45 PM - 4:30 PM	Breakout Session 1	multiple locations, see digital program or app
4:45 PM - 5:30 PM	Breakout Session 2	multiple locations, see digital program or app

SATURDAY, JUNE 11


7:00 AM - 4:15 PM	Registration	Congressional Foyer
7:00 AM - 8:00 AM	Breakfast	Congressional A
8:00 AM - 11:30 AM	Main Stage Presentations	Congressional B
11:30 AM - 12:30 PM	Lunch	Congressional A
12:30 PM - 3:10 PM	Main Stage Presentations	Congressional B
3:25 PM - 4:10 PM	Breakout Session 3	multiple locations, see digital program or app
4:15 PM - 5:00 PM	Breakout Session 4	multiple locations, see digital program or app

Download our Conference Mobile App!


Install the "Eventzilla" app on your phone or tablet by following the links below or by searching for "EventZilla" in the App Store or on Google Play. Once you have installed this app, you will be asked to enter and verify your email address. Be sure to use the same email address that you registered with. Then, follow the instructions and enjoy the App!



The conference app includes information on presentations, speakers, exhibitors, and more. We'll also use the App to send real-time updates throughout the conference.



Meeting Space Floorplan



3RD FLOOR

- Breakfast/Lunch
- Main Stage Presentations
- Breakouts

4TH FLOOR

- Breakouts
- Thu Intro Pre-Lectures

Conference WiFi

Complimentary meeting space wireless internet access is available.

- 1) Navigate to "View available wireless networks"
- 2) Connect to the network name "Fairmont_Meeting"
- 3) A web redirect may prompt you to enter a passcode; if not open a browser and navigate to Fairmont.com
- 4) Enter the password "ASKP32022" and click the blue button

This will give you access to the Wi-Fi network for the duration of the event. If you encounter any issues, please reach out to Encore at 512.674.1589.

PROGRAM - THURSDAY, JUNE 9

12:00 PM- 7:00 PM Registration

Congressional Foyer

INTRODUCTORY PRE-LECTURES *(Additional Ticket Purchase Required)*

Sage

1:00 PM- 2:00 PM Past & Present of Ketamine Infusion Therapy

Steven L. Mandel, MD, Founder & President, Ketamine Clinics Los Angeles

This session will provide a detailed overview and history of Ketamine Infusion Therapy and how it has evolved into an important treatment today. Pharmacology, route of administration, and who should give and get ketamine will be discussed.

2:00 PM- 3:00 PM Patient Selection

Lisa Harding, MD, Medical Director, Depression MD

Spravato obtained FDA Approval for the treatment of: Treatment-resistant depression (TRD) in adults and later on Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. Intravenous ketamine has been used off label for various psychiatric illnesses. This session is for new practitioners to gain an overview of the Indications for Treatment and the necessity for accurate psychiatric diagnoses prior to treatment initiation. We will look at treatment data related to IVK and Spravato and commonly used Dosing Strategies. The FDA has a robust system to monitor the administration of Esketamine (REMS and regulation) and an overview of that system will be discussed.

3:00 PM- 3:15 PM Break

Congressional Foyer

3:15 PM- 4:15 PM Introduction to Ketamine Assisted Psychotherapy (KAP) and Patient Preparation

Erin Amato, MD, Medical Director, Montana Psychiatry & Brain Health Center

This session will include essential information about ketamine assisted psychotherapy (KAP) practice models, the roles of various medical and psychiatric professionals on the KAP team, determining which patients might be the best fit for a KAP treatment approach, the importance of set and setting, music and the ketamine treatment experience, and the vital role of adequate preparation and integration in creating an optimal treatment experience.

4:15 PM- 5:15 PM Legal Considerations in Initiating Clinical Practice & Considerations when Treating Complex Patients

Sandhya Prashad, MD, Physician, Houston Ketamine Therapeutics

Due to the unique nature of treatment with ketamine, attention to a variety of details is critical when considering using it therapeutically. This session will also include highlighting unique legal considerations. In addition, important factors related to scope and patient selection will be discussed.

6:00 PM- 7:30 PM Welcome Cocktail Reception

Congressional Foyer

Since 2016, Ketamine Media has been the gold standard in helping providers raise awareness about the clinical use of ketamine. Please join ASKP3 & Ketamine Media for Thursday's welcome reception, where one provider will win a sponsored treatment series for one of their patients.

Sponsored by Ketamine Media



PROGRAM - FRIDAY, JUNE 10

7:00 AM- 5:30 PM Registration

Congressional Foyer

7:00 AM- 8:00 AM Breakfast and Special Thought Leader Presentation

Congressional A

The #1 Factor That Separates 7 Figure Psych Ketamine Practices from Everyone Else in the Marketplace
Scott Theaman, Founder, *Beyond Marketing*

After working with over 200+ Ketamine, TMS, and Mental Health Practices since 2018, Scott Theaman and his team have gained an intimate perspective of ketamine clinics across the nation, from owner-operated start-ups to large multi-state, venture-backed enterprises. We've identified the golden thread that separates the top performing clinics from the ones that struggle to get into momentum. This golden thread transcends geography, financial backing, education level and marketing. In this talk, Scott will reveal how you can implement this factor into your practice and start helping more patients than ever before. You'll have confidence, clarity, and peace of mind knowing that regardless of outside forces, your clinic is set up for success.

Sponsored by Beyond Marketing

8:15 AM- 8:30 AM Opening Remarks

Congressional B

Sandhya Prashad, MD, ASKP3 President and Founding Member

8:30 AM - 9:10 AM **Maintaining Ethical and Professional Boundaries with Patients: Issues to Consider** Congressional B
Dominic Sisti, MD, Associate Professor in the Department of Medical Ethics & Health Policy, Perelman School of Medicine at the University of Pennsylvania

Questions about if, when, and how to touch patients in psychedelic and ketamine treatment have generated controversy, scandal, and apprehension. In this talk, I will first discuss the ethical and philosophical aspects of the clinical encounter that ground clear boundaries and make sexual touch ethically impermissible. I'll then offer recommendations for therapeutic touch that is patient-centered and evidence-based. I will conclude with a discussion about educational and regulatory gaps that need to be addressed to protect patients and avoid continued confusion and scandal as the field expands.

9:10 AM - 9:20 AM Q&A

Congressional B

9:20 AM - 9:50 AM **Legal Considerations in Ketamine Clinics**

Congressional B

Stuart Miller, JD, Shareholder, *Munsch Hardt*; and **Daniel Sternthal, JD**, Shareholder, *Munsch Hardt*

In this session, we will discuss a few of the most significant legal issues relevant to Ketamine Clinics; including operational and regulatory risks; legal considerations related to transactions; and other Ketamine specific issues. The objectives are to identify legal issues relevant to physicians and others who work in Ketamine space and discuss strategies to address risk and create opportunity.

9:50 AM - 10:00 AM Q&A

Congressional B

10:00 AM - 10:10 AM Break

Congressional Foyer

Have a question for a Main Stage presenter?

Visit [Slido.com](https://www.slido.com) and enter the event code #7955510 to ask a question during the Q&A portion following the session.



PROGRAM - FRIDAY, JUNE 10 (CONT'D)

10:10 AM - 10:40 AM Psychedelic Pharmacology

Congressional B

Jason Wallach, PhD, Assistant Professor of Pharmaceutical Sciences, USciences; and **Hamilton Morris**, journalist, researcher and creator of the television series *Hamilton's Pharmacopeia*

This talk will provide a broad overview of the history and pharmacology of psychedelic drugs with a focus on dissociatives (NMDAR antagonists), classical hallucinogens (5-HT_{2A} agonists) and empathogens (e.g., MDMA). Key representative drugs, as well as their hypothesized mechanisms of action will be discussed with respect to psychoactive and clinical actions. The challenges in understanding mechanisms of action of CNS drugs will also be discussed.

10:40 AM - 10:50 AM Q&A

10:50 AM - 11:20 AM Esketamine and Cognitive Behavioral Therapy

Congressional B

Sam Wilkinson, MD, Physician, Yale University

Several studies have shown that ketamine can produce rapid-antidepressant effects; esketamine has now received regulatory approval as a therapy for treatment-resistant depression. Both of these treatments presumably work by enhancing neuroplasticity, potentially leading to a period wherein adaptive learning is enhanced. This may present an opportune window wherein psychotherapeutic goals could be accomplished with greater facility. This presentation reviews the literature with respect to combining ketamine/esketamine with psychotherapy.

11:20 AM - 11:30 AM Q&A

Congressional B

11:30 AM - 12:30 PM LUNCH

Congressional A

12:30 PM - 1:00 PM Ketamine and Esketamine: Lessons to Inform Emerging Psychedelic Delivery Models

Congressional B

Steven Levine, MD, SVP of Patient Access and Medical Affairs, Compass Pathways

The unusual case of an industry spawned by the off-label application of a generic drug to new indications with minimal regulation, followed by a fully-regulated and payer-reimbursed version of a similar molecule, has provided many lessons. The ketamine/esketamine story will help inform the development of emerging psychedelic therapies and implications for patient access to innovation.

1:00 PM - 1:10 PM Q&A

Congressional B

1:10 PM - 1:40 PM Psilocybin-Assisted Therapy for Major Depressive Disorder: Current Evidence and Future Directions

Congressional B

Natalie Gukasyan, MD, Assistant Professor, Medical Director, Johns Hopkins Center for Psychedelic and Consciousness Research

A growing body of research has shown that psilocybin-assisted therapy may have rapid and substantial efficacy for major depressive disorder. This talk will review 1) the latest understanding in basic mechanisms driving therapeutic efficacy, 2) the treatment model used in most clinical trials with this modality, and 3) results of major clinical trials to date as well as future directions for this research.

1:40 PM - 1:50 PM Q&A

Congressional B



PROGRAM - FRIDAY, JUNE 10 (CONT'D)

1:50 PM - 2:20 PM Ketamine Therapy: Debate & Implications

Congressional B

Rupert McShane, MD, FRCPsych, Associate Professor, University of Oxford (via Zoom); **Lisa Harding, MD**, Medical Director, Depression MD; and **Sandhya Prashad, MD**, Physician, Houston Ketamine Therapeutics

We are living in an era of medicine where science has outpaced regulation with regard to novel treatment approaches for depression. Dr. McShane- International Expert will join ASKPs President and Vice President in conversation about certification, regulation and the role of ASKP3 in this renaissance of psychedelic medicine

2:20 PM - 2:30 PM Q&A

Congressional B

2:30 PM - 3:00 PM Expanding Scope of Consciousness: Understanding the Neurobiology and Symbolism of Ketamine and Psychedelic States

Congressional B

Jeff Becker, MD, Physician, Jeffrey Becker, MD, Inc.

Ketamine has powerful psychic effects believed to result from relaxing the neuroinhibitory tone that normally reduces and stereotypes waking scope of consciousness. The development of inhibitory patterning and network stereotypies (e.g., default mode, executive and salience networks) is a necessary aspect of early adult development that simultaneously individuates the human psyche while also setting the stage for potential alienation, depression and despair. At sub-anesthetic doses, ketamine preferentially inhibits Chandelier Cells within the inhibitory interneuron net and thereby allows a blooming of new neural interaction across multiple domains of brain function. In many individuals the emerging themes in this state resemble classical spiritual tropes surrounding the Encounter with Self and other ageless transpersonal psychological themes. Ketamine's capacity to dilate the aperture of perception may be a primary mechanism facilitating a return to wholeness. As such, understanding the phenomena involved in the emergence of symbolic meaning during sub-anesthetic ketamine can inform the community at many levels, from applied symbolism in Ketamine Assisted Psychotherapy, to understanding the resolution of paradox in spiritualism, to appreciating the nature of increased GAMMA EEG power seen both in ketamine treatment and committed meditators.

3:00 PM - 3:10 PM Q&A

Congressional B

3:10 PM - 3:45 PM Break

Congressional Foyer

3:45 PM - 4:30 PM BREAKOUT SESSION 1

- **Management of Patients Who Stop Responding and Non-Responders** [Repeated in Breakout 2] Sage
Sandhya Prashad, MD, Physician, Houston Ketamine Therapeutics; and **Lisa Harding, MD**, Medical Director, Depression MD

A subset of patients that initially respond to treatment may stop responding while another 20-30% may not respond at all. Management of these patient subgroups as well as alternatives or augmentation treatments will be discussed.



PROGRAM - FRIDAY, JUNE 10 (CONT'D)

3:45 PM - 4:30 PM BREAKOUT SESSION 1 (CONT'D)

- **Ketamine Services and the Managed Care Model** [Repeated in Breakout 2] Congressional B
Brent Turnipseed, MD, Medical Director and Principal Investigator, Roots Behavioral Health; and **Andrea Turnipseed, LCSW-S**, co-founder and Executive Director of Roots Behavioral Health

Access to behavioral healthcare, psychotherapy, and medication management is often considered a luxury for those who have the time, financial means, and available providers in their community. In order to make ketamine treatment more affordable, providers must begin to work with the financial and insurance models that currently exist. While patient scholarships and private funds are helpful to reduce costs, most people must utilize health insurance to pay for their care. If providers can learn to offer insurance-based treatments, the patient experience is legitimized within their family, work, and social environments, ultimately increasing adherence and long-term benefits. This session will give an overview of working with managed care so that patients can realize the full potential of ketamine by making it more accessible to the community at large.

- **Ketamine & Pain** [Repeated in Breakout 2] Poppy
Nykol Bailey, CRNA, PMHNP, Owner/Operator, Boise Ketamine Clinic; and **Steven Mandel, MD**, KCLA Founder & President and Medical Director, Ketamine Clinics Los Angeles

Breakout discussion talking about current research, various protocols and approaches for the use of ketamine for pain conditions.

- **Incorporating Functional and Integrative Mental Health Treatments into Ketamine-Related Care** Primrose
[Repeated in Breakout 2]
Erin Amato, MD, Medical Director, Montana Psychiatry & Brain Health Center; and **Jeff Becker, MD**, Physician, Jeffrey Becker, MD, Inc.

The presenters will discuss strategies incorporating nutritional laboratory assessment, genetic analysis, supplement prescriptions and integrative techniques in support of ketamine-based mental health care treatment.

- **Opening Space for Parts: Ketamine-Assisted Internal Family Systems Therapy** Congressional A
Nicholas Bruss, EdD, LMFT, Speaker and Psychotherapist

Internal Family Systems (IFS) is a powerful, non-pathologizing, evidence-based model of psychotherapy that is synergistic with psychedelic-assisted treatments. Combining ketamine with IFS can accelerate a healing process by growing relationships with the inner parts that hold entrenched limiting beliefs and/or that maintain painful habits. Drawing on his practice of IFS since 2013, and working with ketamine since 2017, Dr. Bruss will introduce the IFS model and discuss the benefits, challenges and limitations of ketamine-assisted IFS therapy.



PROGRAM - FRIDAY, JUNE 10 (CONT'D)

4:45 PM - 5:30 PM BREAKOUT SESSION 2

• Management of Patients Who Stop Responding and Non-Responders

Sage

Sandhya Prashad, MD, Physician, Houston Ketamine Therapeutics; and **Lisa Harding, MD**, Medical Director, Depression MD

A subset of patients that initially respond to treatment may stop responding while another 20-30% may not respond at all. Management of these patient subgroups as well as alternatives or augmentation treatments will be discussed.

• Ketamine Services and the Managed Care Model

Congressional B

Brent Turnipseed, MD, Medical Director and Principal Investigator, Roots Behavioral Health; and **Andrea Turnipseed, LCSW-S**, co-founder and Executive Director of Roots Behavioral Health

Access to behavioral healthcare, psychotherapy, and medication management is often considered a luxury for those who have the time, financial means, and available providers in their community. In order to make ketamine treatment more affordable, providers must begin to work with the financial and insurance models that currently exist. While patient scholarships and private funds are helpful to reduce costs, most people must utilize health insurance to pay for their care. If providers can learn to offer insurance-based treatments, the patient experience is legitimized within their family, work, and social environments, ultimately increasing adherence and long-term benefits. This session will give an overview of working with managed care so that patients can realize the full potential of ketamine by making it more accessible to the community at large.

• Ketamine & Pain

Poppy

Nykol Bailey, CRNA, PMHNP, Owner/Operator, Boise Ketamine Clinic; and **Steven Mandel, MD**, KCLA Founder & President and Medical Director, Ketamine Clinics Los Angeles

Breakout discussion talking about current research, various protocols and approaches for the use of ketamine for pain conditions.

• Incorporating Functional and Integrative Mental Health Treatments into Ketamine-Related Care

Primrose

Erin Amato, MD, Medical Director, Montana Psychiatry & Brain Health Center; and **Jeff Becker, MD**, Physician, Jeffrey Becker, MD, Inc.


The presenters will discuss strategies incorporating nutritional laboratory assessment, genetic analysis, supplement prescriptions and integrative techniques in support of ketamine-based mental health care treatment.

• Ketamine Assisted Psychotherapy- Challenging Cases [Repeated in Breakout 4]

Congressional A

Phil Wolfson, MD, Director, Center for Transformational Psychotherapy and founder of Ketamine Assisted Psychotherapy; and **Tatiana Santini, MA**, Ketamine Assisted Psychotherapist, Hive

Dr. Wolfson has been a significant explorer and developer in ketamine therapy and has the benefit of decades of experience and observation. Tatiana Santini is a registered Psychotherapist and has completed Dr. Wolfson's KTC Training and several other highly regarded psychedelic therapy training programs. Come learn from them both as they share best practices and lessons learned.



PROGRAM - SATURDAY, JUNE 11

7:00 AM- 4:15 PM Registration

Congressional Foyer

7:00 AM- 8:00 AM Breakfast

Congressional A

8:00 AM - 8:30 AM Ketamine and Opioid Dependence: A New Frontier?

Congressional B

Randall Malchow, MD, Medical Director, AMG Ketamine and Wellness

This presentation will begin with a review of the opioid epidemic, how opioid induced hyperalgesia differs from tolerance and addiction, and evidence against the use of chronic opioids for chronic pain. The discussion will address symptoms and treatment of opioid withdrawal and the standard approaches to opioid use disorder in the U.S. Finally, information will be provided on the existing evidence for the use of ketamine for opioid dependence as well as our protocol that has been developed and implemented over the past 6 years.

8:30 AM- 8:40 AM Q&A

Congressional B

8:40 AM - 9:10 AM Ketamine for Migraine and Headache Disorders

Congressional B

Nykol Bailey, CRNA, PMHNP, Owner/Operator, Boise Ketamine Clinic; and **Patrick Sullivan, DO**, Medical Director, Initia Nova Medical Solutions, LLC

Discussion around the approach to treatment for migraine, refractory headache disorders and other headache variants, and how ketamine may be a part of the treatment plan. This session will discuss proper diagnosis, how to identify red flags and avoid pitfalls, and how and when to utilize ketamine.

9:10 AM - 9:20 AM Q&A

Congressional B

9:20 AM - 9:50 AM Ketamine Assisted Psychotherapy—the Primacy of the Subjective

Congressional B

Phil Wolfson, MD, Director, Center for Transformational Psychotherapy and founder of Ketamine Assisted Psychotherapy

KAP is the first contemporary legal psychedelic medicine to offer the possibility of a deep connection to human suffering, imagination, trauma, meditative consciousness--and as a result living one's life with compassion, humility and equanimity. Sharing our soul lives with each other, collaborating and connecting, these are the fundamentals for moving towards a progressive and egalitarian society that enables personal and planetary realization.

9:50 AM - 10:00 AM Q&A

Congressional B

10:00 AM - 10:10 AM Break

Congressional Foyer



PROGRAM - SATURDAY, JUNE 11 (CONT'D)

10:10 AM - 10:40 AM Esketamine: A Conversation About Access to Care

Congressional B

Lisa Harding, MD, Medical Director, Depression MD

In 2019, Esketamine CIII Nasal Spray is a non-competitive N-methyl D-aspartate (NMDA) receptor antagonist, in conjunction with an oral antidepressant, obtained FDA Approval for the treatment of: Treatment-resistant depression (TRD) in adults and later on Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. Access to health care means having "the timely use of personal health services to achieve the best health outcomes." Uninsured patients and patients within lower socioeconomic groups are less likely to receive high quality medical care and more likely to have poor health status with regard to chronic illnesses that require maintenance treatments. The process may vary across systems and individualized management plans would need to be made depending on the person's assets, disabilities, nature and severity of depression. Many patients with depression end up in a "fail-first" loop before they can access treatments recommended by their care team. This session will focus on challenges affecting these subgroups and how to formulate an action plan to address these barriers to care, examining where esketamine fits into this paradigm.

10:40 PM - 10:50 PM Q&A

Congressional B

10:50 AM - 11:20 AM Challenges and Opportunities for Collaborative Care in the Delivery of Ketamine/Esketamine Therapy

Congressional B

Brandon Kitay, MD, Assistant Professor, Emory University School of Medicine and Director of Behavioral Health Integration, Emory Healthcare

The need for expanded mental health access has breached the public consciousness but significant barriers at the levels of patient, provider, and system preclude a tractable, "one size fits all" solution. Collaboration across subspecialties and disciplines along with formal mechanisms to better integrate mental and physical health afford opportunities to address the problem of access while scaling limited resources. This session will explore the barriers and opportunities for collaboration and integration, from individual patient referral through population-based management, specifically for improving ketamine/esketamine therapy access and outcomes.

11:20 AM - 11:30 AM Q&A

Congressional B

11:30 PM - 12:30 PM Lunch

Congressional A

12:30 PM - 1:00 PM Ketamine and Late-Life Depression: Perspectives on Recent Research

Congressional B

Sanjay Mathew, MD, Physician, Baylor College of Medicine

There have been relatively few randomized controlled trials of ketamine and esketamine in elderly patients with treatment-resistant depression. A Phase 3 trial of esketamine nasal spray in late-life TRD was negative for the primary outcome, and a recent comparative trial of IV ketamine and ECT found markedly lower response rates in the oldest patients treated with ketamine. This session reviews recent data in late-life depression including a ketamine dose-finding study with concurrent neurophysiological biomarkers. The session concludes with a discussion of challenges and future directions.

1:00 PM - 1:10 PM Q&A

Congressional B



PROGRAM - SATURDAY, JUNE 11 (CONT'D)

1:10 PM - 1:40 PM Emerging Depression Treatment: Ketamine for Treatment-Resistant Depression in Adolescents

Congressional B

Michael Bloch, MD, Psychiatrist, Yale University

This session will examine the evidence-base concerning previous key clinical trials and treatment issues in adolescent depression. It will also examine primary and secondary results from the first single-dose, randomized, controlled, crossover trial in adolescent depression.

1:40 PM - 1:50 PM Q&A

Congressional B

1:50 PM - 2:20 PM Outcomes of Ketamine Intravenous Therapy (KIT) for Depression and Anxiety in the Real-World Part II

Congressional B

L. Alison McInnes, MD, VP of Medical Affairs, Osmind

We are evaluating outcomes of KIT for depression in increasingly larger real-world data sets and refer to this project as the Osmind/Stanford Real-World Ketamine Analyses (ORKA) staged approach. As we progress, we find that the most compelling patient centric goal is to identify clinical predictors of remission, response or non-response that may help couch a patient's expectations about the treatment. In the current talk we will present depression and anxiety outcomes derived from an independent data set, following on our first paper McInnes et al. 2022, and develop our thinking about response prediction.

2:20 PM - 2:30 PM Q&A

Congressional B

2:30 PM - 3:00 PM Clinical Effectiveness of Intravenous Racemic Ketamine Infusions in a Large Community Sample with Suicidal Ideation, TRD, and Generalized Anxiety Disorder

Congressional B

Patrick Oliver, MD, Medical Director, MindPeace Clinics

Dr. Oliver of MindPeace Clinics has partnered with VCU to publish one of the largest studies of ketamine in a community setting. The paper evaluates the results of 424 patients.

3:00 PM - 3:10 PM Q&A

Congressional B

3:10 PM - 3:25 PM Break

Congressional Foyer


3:25 PM - 4:10 PM BREAKOUT SESSION 3

• TMS & Ketamine Used in Combination

Primrose

Sandhya Prashad, MD, Physician, Houston Ketamine Therapeutics; and **Patrick Sullivan, DO**, Medical Director, Initia Nova Medical Solutions, LLC

Patients that fail to respond to a single treatment modality may respond when these treatments are used in combination. This is considered a novel treatment. The underlying mechanism of action, patient selection and specific techniques will be discussed in this session.



PROGRAM - SATURDAY, JUNE 11 (CONT'D)

3:25 PM - 4:10 PM BREAKOUT SESSION 3 (CONT'D)

- **Billing and Insurance**

Congressional B

Lisa Harding, MD, Medical Director, Depression MD

Changes to evaluation and management (E/M) coding took effect on Jan. 1, 2021. New guidelines now allow providers to select an E/M code based on total time spent on the date of the encounter or medical decision-making. As a continuation of her mainstage lecture, Dr. Harding breaks down challenges in accepting insurance and how to approach billing. She offers a structured approach to help you think about accepting insurance coverage for treatments for your patients.

- **Difficult Cases/ Personality Disorders/ Boundaries** [Repeated in Breakout 4]

Sage

Erin Amato, MD, Medical Director, Montana Psychiatry & Brain Health Center; and **John Dougherty III, DO**, Psychiatrist, Initia Nova Delaware

Every health professional will care for patients with personality disorders. Fifty percent of major depressive patients, 52% of dysthymic patients, and 69% of patients with double depression were diagnosed as having at least one personality disorder. Patients with a personality disorder had higher scores on the Beck Anxiety and Depression Inventories. Symptoms of BPD first emerge during childhood or adolescence, normally increase after the onset of puberty, peak during early adulthood, and decline during subsequent decades. By age 16, 1.4% of adolescents in a prospective community-based longitudinal study met criteria for BPD, and the cumulative prevalence doubled during the remainder of adolescence into the early twenties. While BPD features rise and fall between childhood and adulthood, those who develop more significant personality dysfunction early in life are most likely to develop significant functional impairment academically, occupationally, and socially regardless of the decline in symptoms. Understanding the role of personality disorders and boundaries in the setting of intervention procedures in psychiatry is important in understanding response to treatment.

- **Mastering Hybrid Intramuscular Dosing in Ketamine Assisted Psychotherapy**

Sage

Jeff Becker, MD, Physician, Jeffrey Becker, MD, Inc.; and **Gita Vaid, MD, PC**, Psychiatrist

The session will discuss the protocol and technique of hybrid intramuscular dosing in ketamine assisted psychotherapy. Discussion of dosing ranges, dosing intervals and the nuances of attunement to the patient's experience during the session will be discussed. In addition the potential value of this model in providing windows of therapeutic contact during the psychotherapeutic process to capture psychic content for use in the therapeutic relationship will be explored.

- **Where Does Ketamine Fit in the Future Psychedelic Landscape?** [Repeated in Breakout 4]

Congressional A

Abid Nazeer, MD, Chief Medical Officer, Wesana Health / APS Ketamine

There has been major growth in the field, and acceptance of using ketamine for the treatment of psychiatric diagnosis over the past 5 years. Ketamine related compounds are being studied by researchers and developed by pharmaceutical companies. The number of clinics and providers that offer some form of ketamine therapy has been exponentially increasing. More general public awareness and adoption of this new treatment approach is being seen. Ketamine was the first drug to successfully introduce the concepts of altered states of consciousness and neuroplasticity to mainstream psychiatric healthcare. The efficacy of Ketamine in treating these conditions has helped the process immensely, and it has been serving as a stepping stone into future psychedelic medicines being studied. These future medicines share the same general approach to ketamine treatment, helping to get to the root cause of trauma. Altered states of consciousness are being utilized with psychotherapy to yield initial benefits that surpass ketamine. Will Ketamine have its own place in the future landscape and what will that look like?



PROGRAM - SATURDAY, JUNE 11 (CONT'D)

4:15 PM - 5:00 PM BREAKOUT SESSION 4

• Ketamine Assisted Psychotherapy - Research, Frameworks and Application

Primrose

Brittany O'Brien, PhD, Psychologist, Baylor College of Medicine; and **Rena Beyer, MSW, LCSW**, Psychotherapist, Fostering Greatness

A small, but growing, body of research has focused on the potential benefits of combining ketamine treatment with psychotherapy. This session will provide a brief overview of the combination of pharmacotherapy and psychotherapy, highlighting aspects relevant to ketamine assisted psychotherapy.

• Difficult Cases/ Personality Disorders/ Boundaries

Sage

Erin Amato, MD, Medical Director, Montana Psychiatry & Brain Health Center; and **John Dougherty III, D.O.**, Psychiatrist, Initia Nova Delaware

Every health professional will care for patients with personality disorders. Fifty percent of major depressive patients, 52% of dysthymic patients, and 69% of patients with double depression were diagnosed as having at least one personality disorder. Patients with a personality disorder had higher scores on the Beck Anxiety and Depression Inventories. Symptoms of BPD first emerge during childhood or adolescence, normally increase after the onset of puberty, peak during early adulthood, and decline during subsequent decades. By age 16, 1.4% of adolescents in a prospective community-based longitudinal study met criteria for BPD, and the cumulative prevalence doubled during the remainder of adolescence into the early twenties. While BPD features rise and fall between childhood and adulthood, those who develop more significant personality dysfunction early in life are most likely to develop significant functional impairment academically, occupationally, and socially regardless of the decline in symptoms. Understanding the role of personality disorders and boundaries in the setting of intervention procedures in psychiatry is important in understanding response to treatment.

• Esketamine in Private Practice: Cases from the Experts

Poppy

Lisa Harding, MD, Medical Director, Depression MD; and **Sandhya Prashad, MD**, Physician, Houston Ketamine Therapeutics


Esketamine CIII Nasal Spray is a non-competitive N-methyl D-aspartate (NMDA) receptor antagonist indicated, in conjunction with an oral antidepressant, for the treatment of: Treatment-resistant depression (TRD) in adults and Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. The TRD indication was achieved in 2019 and the MDD indication followed soon after. Dr. Amato, Dr. Harding and Dr. Prashad have been using esketamine in their practices since its approval. Join for a robust conversation about implementation, appropriate patients, response rate and nuances of use.

• Ketamine Assisted Psychotherapy- Challenging Cases

Congressional B

Phil Wolfson, MD, Director, Center for Transformational Psychotherapy and founder of Ketamine Assisted Psychotherapy; and **Tatiana Santini, MA**, Ketamine Assisted Psychotherapist, Hive

Dr. Wolfson has been a significant explorer and developer in ketamine therapy and has the benefit of decades of experience and observation. Tatiana Santini is a registered Psychotherapist and has completed Dr. Wolfson's KTC Training and several other highly regarded psychedelic therapy training programs. Come learn from them both as they share best practices and lessons learned.



PROGRAM - SATURDAY, JUNE 11 (CONT'D)

4:15 PM - 5:00 PM BREAKOUT SESSION 4 (CONT'D)

- **Where Does Ketamine Fit in the Future Psychedelic Landscape?**

Congressional A

Abid Nazeer, MD, Chief Medical Officer, Wesana Health / APS Ketamine

There has been major growth in the field, and acceptance of using ketamine for the treatment of psychiatric diagnosis over the past 5 years. Ketamine related compounds are being studied by researchers and developed by pharmaceutical companies. The number of clinics and providers that offer some form of ketamine therapy has been exponentially increasing. More general public awareness and adoption of this new treatment approach is being seen. Ketamine was the first drug to successfully introduce the concepts of altered states of consciousness and neuroplasticity to mainstream psychiatric healthcare. The efficacy of Ketamine in treating these conditions has helped the process immensely, and it has been serving as a stepping stone into future psychedelic medicines being studied. These future medicines share the same general approach to ketamine treatment, helping to get to the root cause of trauma. Altered states of consciousness are being utilized with psychotherapy to yield initial benefits that surpass ketamine. Will Ketamine have its own place in the future landscape and what will that look like?



WHY CHOOSE Ketamine Media?

Trust Takes Time to **Grow**. Let's **Nurture** it Together.

Ketamine Media is leading the way in helping providers raise awareness about the clinical use of ketamine.

The Industry's First Agency

Largest Network of Partners

Industry-Leading Data

Purpose-Driven Organization

Industry Leader in Inquiries

Patient-Centered Experience

Operating Capital

Clinic Acquisition Strategies



KETAMINE MEDIA Family Tree



1 (800) 975-2291 | contact@ketaminemedia.com
611 King Street, Knoxville TN 37311

YOU'RE INVITED
ASKP³
AFTER PARTY

Join us for cocktails

FRIDAY JUNE 10, 2022

7:30 - 10:30 PM

MEXIC-ARTE MUSEUM

419 CONGRESS AVE

Supported by a donation from Bexson Biomedical



**TRANSFORMING
KETAMINE PRACTICES**
into thriving businesses

Grow your ketamine practice into a thriving 7-figure business with done-for-you marketing, business development training, and unparalleled lead management software.

www.BeyondMarketing.net



Meet the Team

Scott Theaman, Adrian Hill, Brynda Mortimer,
Sebastian Yepes, Justin Cooper



Our Sponsors



GOLD LEVEL



SILVER LEVEL



BRONZE LEVEL
